|
Canada-0-TileNonCeramicDistributors företaget Kataloger
|
Företag Nyheter:
- Agios
Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs Our mature and unique understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together
- Agios Pharmaceuticals Inc. - MarketWatch
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development
- Agios Pharmaceuticals Stock Declines 23% in 6 Months: Heres Why
Shares of Agios Pharmaceuticals AGIO have plunged 23% over the past six months, primarily due to pipeline and regulatory setbacks, which have dampened investor confidence in the company’s near
- Agios Pharmaceuticals (AGIO) Stock Price, News Analysis
Should You Buy or Sell Agios Pharmaceuticals Stock? Get The Latest AGIO Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat
- Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue . . . - Nasdaq
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +7 77% and +27 69%, respectively, for the quarter ended September 2025 Do the numbers hold clues to what lies ahead for
- AGIO: Agios Pharmaceuticals Inc - Stock Price, Quote and News - CNBC
Get Agios Pharmaceuticals Inc (AGIO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC
- Agios Pharmaceuticals - LinkedIn
Fueled by Connections to Transform Rare Diseases™ | Agios is a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment
- Agios Pharmaceuticals Inc. Stock Grades | AGIO | Barrons
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development It focuses on cellular
- Agios Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical trials . . .
Agios Pharmaceuticals appears stuck in regulatory limbo after the FDA missed an already-delayed Dec 7 target date on its supplemental application for Pyrukynd (mitapivat) in adult patients with alpha- or beta-thalassemia
- About Us – Agios
Agios was founded in 2008 to unlock a new field of discovery in cellular metabolism This singular focus on metabolic disease has taken us from the development of precision therapies in oncology to pioneering new investigational medicines for the treatment of rare diseases
|
|